How is TALVEY® (talquetamab-tgvs) different?

TALVEY® (talquetamab-tgvs) is the first and only FDA-approved bispecific antibody that targets GPRC5D for the treatment of relapsed or refractory multiple myeloma.

How does TALVEY® work?

Multiple myeloma cell with proteins GPRC5D and BCMA identified, graphic

Multiple myeloma cells have different proteins on their surface. You might be familiar with one of these proteins called BCMA. GPRC5D is another protein that can be found on multiple myeloma cells (as well as some healthy cells in your body), and it is offering a different option for multiple myeloma treatment.

T-cell with protein CD3 identified, graphic

Cells in your body also have different proteins on their surface. T cells, which are part of your immune system, have a protein called CD3.

TALVEY® works with your body to help it recognize and destroy multiple myeloma cells.

TALVEY® attaches to the GPRC5D proteins on multiple myeloma cells and the CD3 proteins on your T cells. By attaching to both of these proteins, TALVEY® can activate your immune system to help destroy the multiple myeloma cells in your body.

TALVEY® attaching to the GPRC5D protein on a multiple myeloma cell and the CD3 protein on a T cell, graphic
TALVEY® activating the immune system to help destroy the multiple myeloma cell, graphic
TALVEY® attaching to the GPRC5D protein on a multiple myeloma cell and the CD3 protein on a T cell, graphic

See the science behind the TALVEY® mechanism of action

BCMA, B-cell maturation antigen; CD, cluster of differentiation; GPRC5D, G protein-coupled receptor class C group 5 member D; HCP, healthcare provider; REMS, Risk Evaluation and Mitigation Strategy.